SCHEMBL1506304

SCHEMBL1506304

CNC(=O)Cc1cc(Nc2cccc(Cl)c2F)nn1-c1ccnc(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.42
▸ RIPK1 Q13546 6/20 0.40
▸ ERBB2 P04626 6/20 0.39
▸ GAK O14976 1/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ LYN P07948 1/20 0.39
▸ RET P07949 1/20 0.39
▸ EPHA1 P21709 1/20 0.39
▸ ERBB3 P21860 1/20 0.39
▸ EPHA2 P29317 1/20 0.39
▸ EPHB2 P29323 1/20 0.39
▸ EPHA5 P54756 1/20 0.39
▸ EPHB4 P54760 1/20 0.39
▸ EPHA4 P54764 1/20 0.39
▸ ADK P55263 1/20 0.39
▸ PTK6 Q13882 1/20 0.39
▸ RIPK3 Q9Y572 1/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506082 0.91 P2RX7 (0.45) P2RX7RIPK1ERBB2IDO1HDAC3
SCHEMBL10010359 0.89 P2RX7 (0.40) P2RX7RIPK1ERBB2GAKRIPK2
SCHEMBL1506212 0.89 RIPK1 (0.43) P2RX7RIPK1ERBB2GAKRIPK2
SCHEMBL10008796 0.88 MAPK1 (0.39) P2RX7RIPK1ERBB2GAKRIPK2
SCHEMBL1506129 0.88 P2RX7 (0.42) P2RX7RIPK1ERBB2GAKRIPK2
SCHEMBL1506079 0.86 IDO1 (0.41) P2RX7RIPK1EGFRIDO1HDAC3
SCHEMBL1506117 0.86 RIPK1 (0.41) P2RX7RIPK1IDO1HDAC3HDAC1
SCHEMBL1506211 0.84 IDO1 (0.40) P2RX7RIPK1EGFRIDO1HDAC3
SCHEMBL10009079 0.84 ERBB2 (0.39) P2RX7RIPK1ERBB2EGFRIDO1
SCHEMBL10010222 0.82 IDO1 (0.39) P2RX7RIPK1EGFRIDO1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 P2RX7 43/4885RIPK1 2211/4885ERBB2 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback